New pastille could change head and neck cancer treatment
Disease control
Not yet recruiting
This large Phase 3 trial is testing a new drug called APG-157, given as a pastille that dissolves in the mouth, for people with advanced head and neck cancer. The study will see if adding APG-157 before and after standard treatments (surgery or chemoradiation) helps keep the canc…
Phase: PHASE3 • Sponsor: Aveta Biomics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 04:00 UTC